Want to see HUMA full AI Analyst Report?
HUMA Stock Chart & Stats
$0.62
-$0.01(-2.16%)
At close: 4:00 PM EDT
$0.62
-$0.01(-2.16%)
Day’s Range― - ―
52-Week Range$0.55 - $2.76
Previous CloseN/A
Volume2.57M
Average Volume (3M)13.56M
Market Cap
$181.76M
Enterprise Value$137.25
Total Cash (Recent Filing)$48.54M
Total Debt (Recent Filing)$65.90M
Price to Earnings (P/E)―
Beta2.96
Next Earnings
Aug 17, 2026EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.59
Shares Outstanding269,638,150
10 Day Avg. Volume5,876,584
30 Day Avg. Volume13,560,694
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)48.86
Price to Sales (P/S)74.54
P/FCF Ratio-1.43
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$1.96Price Target Upside215.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.34
Revenue Forecast (FY)$6.35M
Bulls Say, Bears Say
Bulls Say
Positive Phase 3 V012 Interim Dialysis ResultsA positive, protocol-driven early stop and primary endpoint win materially de-risks the dialysis indication pathway. Successful V012 results enable a supplemental BLA submission and position Humacyte to enter a large, recurring hemodialysis market with an off‑the‑shelf graft that can reduce infections and catheter use, creating durable commercial demand and clearer regulatory trajectory.
FDA Acceptance Of IND For CTEV CABG StudyIND acceptance for a coronary tissue engineered vessel expands Humacyte's addressable market into coronary bypass, validating regulatory progress and enabling clinical proof-of-concept in a high-value surgical segment. Successful CTEV development would diversify revenue sources and leverage existing manufacturing capability, supporting long-term platform value.
Early Commercial Traction: Symvess Unit GrowthConsistent unit growth and expanding site adoption indicate initial product-market fit and the start of surgeon and hospital network effects. Early commercial traction, combined with strengthened commercial leadership, provides a foundation for scaling distribution, surgeon training, and payer engagement—key durable drivers of recurring product sales if sustained.
Bears Say
Very High Cash Burn And Negative Operating Cash FlowPersistent, large negative operating and free cash flows imply ongoing reliance on external financing to fund operations and commercialization. Over multiple quarters this pressures liquidity, increases dilution risk, constrains strategic flexibility, and forces prioritization of programs, which can slow commercialization and pipeline investments if funding lapses.
High Leverage Relative To EquityDebt levels materially exceeding equity reduce financial resilience and raise refinancing or covenant risk, particularly given negative cash flows. High leverage limits capital allocation choices, may increase funding costs, and heightens vulnerability to adverse clinical or commercial setbacks, undermining long-term operational stability.
Commercial Revenue Remains Modest; Uptake Must AccelerateLow absolute sales despite percentage gains show commercialization is nascent and dependent on sustained surgeon adoption, reimbursement, and procurement cycles. Slow uptake prolongs the period before positive gross margins and operating leverage, increasing reliance on external capital and making future scaling and profitability more uncertain.
Humacyte News
HUMA FAQ
What was Humacyte’s price range in the past 12 months?
Humacyte lowest stock price was $0.55 and its highest was $2.75 in the past 12 months.
What is Humacyte’s market cap?
Humacyte’s market cap is $181.76M.
When is Humacyte’s upcoming earnings report date?
Humacyte’s upcoming earnings report date is Aug 17, 2026 which is in 18 days.
How were Humacyte’s earnings last quarter?
Humacyte released its earnings results on May 13, 2026. The company reported -$0.09 earnings per share for the quarter, beating the consensus estimate of -$0.116 by $0.026.
Is Humacyte overvalued?
According to Wall Street analysts Humacyte’s price is currently Undervalued.
Does Humacyte pay dividends?
Humacyte does not currently pay dividends.
What is Humacyte’s EPS estimate?
Humacyte’s EPS estimate is -0.1.
How many shares outstanding does Humacyte have?
Humacyte has 269,638,150 shares outstanding.
What happened to Humacyte’s price movement after its last earnings report?
Humacyte reported an EPS of -$0.09 in its last earnings report, beating expectations of -$0.116. Following the earnings report the stock price went up 24.176%.
Which hedge fund is a major shareholder of Humacyte?
Currently, no hedge funds are holding shares in HUMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Humacyte Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$1.96 (215.86% Upside)
$1.96 (215.86% Upside)
Blogger Sentiment
Bullish
HUMA Sentiment 70%
Sector Average 65%
Sector Average 65%
Hedge Fund Trend
Increased
By 5.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $59.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 1.1%
Last 30 Days ▲ 1.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-76.62%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-31.99%
Trailing 12-Months
Company Description
Humacyte
Humacyte, Inc. focuses on developing and manufacturing readily available, implantable human tissues engineered in a laboratory setting. These bioengineered tissues are designed to treat a wide array of diseases and conditions across various anatomical locations and therapeutic fields. The company employs its distinct scientific and proprietary technology platform to produce human acellular vessels (HAVs). These investigational HAVs are specifically crafted for universal compatibility, enabling easy implantation into any patient without inducing an immune rejection or an adverse foreign body response. Humacyte is currently building a pipeline of HAVs targeting the substantial market for vascular repair, reconstruction, and replacement. This includes applications such as treating vascular trauma, providing arteriovenous access for hemodialysis, addressing peripheral arterial disease, and facilitating coronary artery bypass grafting. Furthermore, the company is exploring the use of its HAVs for pediatric heart surgeries and for cellular therapeutic delivery, including the transplantation of pancreatic islet cells to manage Type 1 diabetes. Founded in 2004, Humacyte maintains its headquarters in Durham, North Carolina.
HUMA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted tangible commercial momentum (Symvess unit and revenue growth), strengthened commercial leadership, international regulatory progress (Israel MAA accepted), strategic government interest (DoD funding), and important near-term clinical catalysts (V012 interim results due June 11 and CTEV Phase I/II planned H2 2026). These operational and pipeline advances were balanced against financial headwinds in the quarter: a swing to a $17.6M net loss driven largely by reduced noncash other income, a large inventory reserve that inflated COGS, increased R&D spend for CTEV manufacturing, and modest absolute product revenue despite high percentage growth. The company has taken actions (restructuring, senior hires, targeted commercialization) to address uptake and cost structure and reported a cash position of $48.9M. Overall, progress on product, pipeline, and commercialization initiatives combined with cost-saving actions and an upcoming trial readout lead to a cautiously optimistic view of the company’s near-term prospects, tempered by the recent negative impact on profitability and remaining timing uncertainties around regulatory and procurement milestones.View all HUMA earnings summariesHUMA Stock 12 Month Forecast
Average Price Target
$1.96
▲(215.86% Upside)
Technical Analysis
Cartesian Therapeutics
―
Allogene Therapeutics
―
―
Foghorn Therapeutics
―
Kyverna Therapeutics, Inc.
―
Ownership Overview
8.14% Insiders
4.80% Mutual Funds
0.09% Other Institutional Investors
81.87% Public Companies and
Individual Investors